171 related articles for article (PubMed ID: 38462629)
1. Efficacy and safety of PD-1 blockade plus long-course chemoradiotherapy in locally advanced rectal cancer (NECTAR): a multi-center phase 2 study.
Yang Z; Gao J; Zheng J; Han J; Li A; Liu G; Sun Y; Zhang J; Chen G; Xu R; Zhang X; Liu Y; Bai Z; Deng W; He W; Yao H; Zhang Z
Signal Transduct Target Ther; 2024 Mar; 9(1):56. PubMed ID: 38462629
[TBL] [Abstract][Full Text] [Related]
2. Rationale and design of a prospective, multicenter, phase II clinical trial of safety and efficacy evaluation of long course neoadjuvant chemoradiotherapy plus tislelizumab followed by total mesorectal excision for locally advanced rectal cancer (NCRT-PD1-LARC trial).
Yang Z; Zhang X; Zhang J; Gao J; Bai Z; Deng W; Chen G; An Y; Liu Y; Wei Q; Han J; Li A; Liu G; Sun Y; Kong D; Yao H; Zhang Z
BMC Cancer; 2022 Apr; 22(1):462. PubMed ID: 35477432
[TBL] [Abstract][Full Text] [Related]
3. [Short-term outcome of programmed cell death protein1 (PD-1) antibody combined with total neoadjuvant chemoradiotherapy in the treatment of locally advanced middle-low rectal cancer with high risk factors].
Li YJ; Zhang L; Dong QS; Cai Y; Zhang YZ; Wang L; Yao YF; Zhang XY; Li ZW; Li YH; Sun YS; Wang WH; Wu AW
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Nov; 24(11):998-1007. PubMed ID: 34823301
[No Abstract] [Full Text] [Related]
4. [Short-course radiotherapy combined with CAPOX and PD-1 inhibitor for the total neoadjuvant therapy of locally advanced rectal cancer: the preliminary single-center findings of a prospective, multicentre, randomized phase II trial (TORCH)].
Wang YQ; Shen LJ; Wan JF; Zhang H; Wang Y; Wu X; Wang JW; Wang RJ; Sun YQ; Tong T; Huang D; Wang L; Sheng WQ; Zhang X; Cai GX; Xu Y; Cai SJ; Zhang Z; Xia F
Zhonghua Wei Chang Wai Ke Za Zhi; 2023 May; 26(5):448-458. PubMed ID: 37217353
[No Abstract] [Full Text] [Related]
5. Interim result of phase II, prospective, single-arm trial of long-course chemoradiotherapy combined with concurrent tislelizumab in locally advanced rectal cancer.
Gao J; Zhang X; Yang Z; Zhang J; Bai Z; Deng W; Chen G; Xu R; Wei Q; Liu Y; Han J; Li A; Liu G; Sun Y; Kong D; Yao H; Zhang Z
Front Oncol; 2023; 13():1057947. PubMed ID: 36816939
[TBL] [Abstract][Full Text] [Related]
6. Total neoadjuvant treatment to increase the clinical complete response rate for distal locally advanced rectal cancer (TESS): A study protocol of a prospective, open-label, multicenter, single-arm, phase 2 trial.
Liu S; Wang X; Zhuang Y; Bai S; Wu X; Ye Y; Luo H; Yu H; Wang Q; Chang H; Zeng Z; Cai P; Pan Z; Gao Y; Chen G; Xiao W
Cancer Med; 2023 Jun; 12(12):13352-13360. PubMed ID: 37156624
[TBL] [Abstract][Full Text] [Related]
7. [Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors].
Ouyang GL; Meng WJ; Shu P; Deng XB; Wu B; Jiang D; Zhuang H; Shen YL; Zhou ZG; Wang ZQ; Wang X
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr; 22(4):349-356. PubMed ID: 31054549
[No Abstract] [Full Text] [Related]
8. Total neoadjuvant therapy with short-course radiotherapy Versus long-course neoadjuvant chemoradiotherapy in Locally Advanced Rectal cancer, Korean trial (TV-LARK trial): study protocol of a multicentre randomized controlled trial.
Kim MJ; Lee DW; Kang HC; Park JW; Ryoo SB; Han SW; Kim KS; Chie EK; Oh JH; Jeong WK; Kim BH; Nam EM; Jeong SY
BMC Cancer; 2023 Aug; 23(1):734. PubMed ID: 37553666
[TBL] [Abstract][Full Text] [Related]
9. [Comparison of short-term efficacy and perioperative safety between neoadjuvant therapy and total neoadjuvant therapy in patients with locally advanced rectal cancer].
Zhai ZW; Zhang KN; Wang C; Han JG; Ma HC; Wei GH; Yang Y; Wang ZJ
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):274-280. PubMed ID: 32192307
[No Abstract] [Full Text] [Related]
10. Galunisertib plus neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: a single-arm, phase 2 trial.
Yamazaki T; Gunderson AJ; Gilchrist M; Whiteford M; Kiely MX; Hayman A; O'Brien D; Ahmad R; Manchio JV; Fox N; McCarty K; Phillips M; Brosnan E; Vaccaro G; Li R; Simon M; Bernstein E; McCormick M; Yamasaki L; Wu Y; Drokin A; Carnahan T; To Y; Redmond WL; Lee B; Louie J; Hansen E; Solhjem MC; Cramer J; Urba WJ; Gough MJ; Crittenden MR; Young KH
Lancet Oncol; 2022 Sep; 23(9):1189-1200. PubMed ID: 35952709
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety-in analysis of short-course radiation followed by mFOLFOX-6 plus avelumab for locally advanced rectal adenocarcinoma.
Shamseddine A; Zeidan YH; El Husseini Z; Kreidieh M; Al Darazi M; Turfa R; Kattan J; Khalifeh I; Mukherji D; Temraz S; Alqasem K; Amarin R; Al Awabdeh T; Deeba S; Jamali F; Mohamad I; Elkhaldi M; Daoud F; Al Masri M; Dabous A; Hushki A; Jaber O; Charafeddine M; Geara F
Radiat Oncol; 2020 Oct; 15(1):233. PubMed ID: 33028346
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of cetuximab, capecitabine and radiotherapy in neoadjuvant treatment of patients with locally advanced resectable rectal cancer.
Velenik V; Ocvirk J; Oblak I; Anderluh F
Eur J Surg Oncol; 2010 Mar; 36(3):244-50. PubMed ID: 20042310
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant capecitabine, radiotherapy, and bevacizumab (CRAB) in locally advanced rectal cancer: results of an open-label phase II study.
Velenik V; Ocvirk J; Music M; Bracko M; Anderluh F; Oblak I; Edhemovic I; Brecelj E; Kropivnik M; Omejc M
Radiat Oncol; 2011 Aug; 6():105. PubMed ID: 21880132
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant PD-1 blockade with sintilimab in mismatch-repair deficient, locally advanced rectal cancer: an open-label, single-centre phase 2 study.
Chen G; Jin Y; Guan WL; Zhang RX; Xiao WW; Cai PQ; Liu M; Lin JZ; Wang FL; Li C; Quan TT; Xi SY; Zhang HZ; Pan ZZ; Wang F; Xu RH
Lancet Gastroenterol Hepatol; 2023 May; 8(5):422-431. PubMed ID: 36870360
[TBL] [Abstract][Full Text] [Related]
15. Anus preservation in low rectal adenocarcinoma based on MMR/MSI status (APRAM): a study protocol for a randomised, controlled, open-label, multicentre phase III trial.
Huang CY; Bai MH; Shen JW; Sun QQ; Feng YR; Chen QP; Mao W; Ju HX; Zhu J
BMC Cancer; 2024 Jan; 24(1):57. PubMed ID: 38200410
[TBL] [Abstract][Full Text] [Related]
16. Safety and tolerability of veliparib combined with capecitabine plus radiotherapy in patients with locally advanced rectal cancer: a phase 1b study.
Czito BG; Deming DA; Jameson GS; Mulcahy MF; Vaghefi H; Dudley MW; Holen KD; DeLuca A; Mittapalli RK; Munasinghe W; He L; Zalcberg JR; Ngan SY; Komarnitsky P; Michael M
Lancet Gastroenterol Hepatol; 2017 Jun; 2(6):418-426. PubMed ID: 28497757
[TBL] [Abstract][Full Text] [Related]
17. Non-operative management after chemoradiotherapy plus consolidation or sandwich (induction with bevacizumab and consolidation) chemotherapy in patients with locally advanced rectal cancer: a multicentre, randomised phase II trial (NOMINATE trial).
Akiyoshi T; Shinozaki E; Taguchi S; Chino A; Hiratsuka M; Tominaga T; Nonaka T; Toda S; Matoba S; Matsui S; Okabayashi K; Mukai T; Hiyoshi Y; Yamaguchi T; Nagasaki T; Yamaguchi K; Ueno M; Kuroyanagi H; Fukunaga Y; Ishizuka N; Konishi T;
BMJ Open; 2022 Mar; 12(3):e055140. PubMed ID: 35304396
[TBL] [Abstract][Full Text] [Related]
18. [Comparison of long-term efficacy between watch and wait strategy and total mesorectal excision in locally advanced rectal cancer patients with clinical complete response after neoadjuvant therapy].
Wang XH; Zhou CJ; Zhang S; Wang QX; Xiao WW; Ding PR; Chen G; Pan ZZ; Zeng ZF; Gao YH
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):266-273. PubMed ID: 32192306
[No Abstract] [Full Text] [Related]
19. A retrospective cohort study of neoadjuvant chemoradiotherapy combined with immune checkpoint inhibitors in locally advanced rectal cancer.
Chen Z; Zou Z; Qian M; Xu Q; Xue G; Yang J; Luo T; Hu L; Wang B
Transl Oncol; 2024 Jun; 44():101955. PubMed ID: 38583351
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancer.
Dellas K; Höhler T; Reese T; Würschmidt F; Engel E; Rödel C; Wagner W; Richter M; Arnold D; Dunst J
Radiat Oncol; 2013 Apr; 8():90. PubMed ID: 23587311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
